Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.72 USD | +0.54% | -7.38% | -10.51% |
Mar. 19 | Transcript : Relmada Therapeutics, Inc., 2023 Earnings Call, Mar 19, 2024 | |
Mar. 19 | Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 3M | Capitalization | 112M |
---|---|---|---|---|---|
Net income 2024 * | -112M | Net income 2025 * | -120M | EV / Sales 2024 * | - |
Net cash position 2024 * | 203M | Net cash position 2025 * | 124M | EV / Sales 2025 * | -4.07 x |
P/E ratio 2024 * |
-1.21
x | P/E ratio 2025 * |
-1.57
x | Employees | 20 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.96% |
Latest transcript on Relmada Therapeutics, Inc.
1 day | +0.54% | ||
1 week | -7.38% | ||
Current month | -20.32% | ||
1 month | -21.00% | ||
3 months | +2.07% | ||
6 months | +17.99% | ||
Current year | -10.51% |
Managers | Title | Age | Since |
---|---|---|---|
Paolo Manfredi
FOU | Founder | 62 | 12-05-30 |
Sergio Traversa
CEO | Chief Executive Officer | 63 | - |
Maged Shenouda
DFI | Director of Finance/CFO | 59 | 15-11-11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 78 | 15-07-13 | |
Sergio Traversa
CEO | Chief Executive Officer | 63 | - |
Maged Shenouda
DFI | Director of Finance/CFO | 59 | 15-11-11 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 0 M€ | 0.00% | - | |
0.03% | 509 M€ | -.--% | ||
0.00% | 237 M€ | +1.78% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 3.705 | +0.14% | 5 897 |
24-04-25 | 3.7 | -4.15% | 85,873 |
24-04-24 | 3.86 | -1.28% | 114,592 |
24-04-23 | 3.91 | +1.03% | 143,632 |
24-04-22 | 3.87 | -3.25% | 178,128 |
Delayed Quote Nasdaq, April 26, 2024 at 09:49 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.51% | 112M | |
-3.07% | 103B | |
-0.34% | 95.71B | |
+1.11% | 22.02B | |
-17.51% | 20.9B | |
-9.14% | 17.85B | |
-42.83% | 16.21B | |
-15.95% | 15.52B | |
+4.77% | 13.86B | |
+31.58% | 12.04B |
- Stock Market
- Equities
- RLMD Stock